Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Cody P Coyne & Lakshmi Narayanan. (2016) Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549). Drug Design, Development and Therapy 10, pages 2575-2597.
Read now
Read now
Preetesh Jain & Susan O'Brien. (2013) Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opinion on Biological Therapy 13:2, pages 169-182.
Read now
Read now
Lukáš Smolej. (2012) The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 21:7, pages 1009-1017.
Read now
Read now
Articles from other publishers (17)
Martin Šimkovič, Pavel Vodárek, Monika Motyčková, Dominika Écsiová, Petra Rozsívalová, Heidi Móciková, Pavla Štěpánková, Alice Sýkorová, Kateřina Hrochová, Filip Vrbacký, David Belada, Pavel Žák & Lukáš Smolej. (2020) Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia. European Journal of Clinical Investigation 51:4.
Crossref
Crossref
Bartosz Puła, Monika Długosz-Danecka, Aleksander Salomon-Perzyński, Agnieszka Szymczyk, Edyta Subocz, Bożena Katarzyna Budziszewska, Justyna Rybka, Lidia Gil, Anna Waszczuk-Gajda, Elżbieta Iskierka-Jażdżewska, Jan M. Zaucha, Michał Osowiecki, Weronika Piszczek, Paweł Steckiewicz, Łukasz Szukalski, Marek Hus, Ewa Lech-Marańda, Wojciech Jurczak & Krzysztof Jamroziak. (2020) Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors. Advances in Medical Sciences 65:2, pages 371-377.
Crossref
Crossref
Farrukh T. Awan & John C. Byrd. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1850
1871.e5
.
Regina Pileckyte, Vilma Valceckiene, Mindaugas Stoskus, Reda Matuzeviciene, Jurgita Sejoniene, Tadas Zvirblis & Laimonas Griskevicius. (2019) Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia. Medicina 55:11, pages 719.
Crossref
Crossref
Rachael B. Rowswell-Turner & Paul M. Barr. (2017) Treatment of chronic lymphocytic leukemia in older adults. Journal of Geriatric Oncology 8:5, pages 315-319.
Crossref
Crossref
Martin Šimkovič, Monika Motyčková, Pavel Vodárek & Lukáš Smolej. (2017) Treatment of elderly and comorbid patients with chronic lymphocytic leukemia. Onkologie 11:3, pages 108-114.
Crossref
Crossref
Susan O'Brien, Jeffrey A Jones, Steven E Coutre, Anthony R Mato, Peter Hillmen, Constantine Tam, Anders Österborg, Tanya Siddiqi, Michael J Thirman, Richard R Furman, Osman Ilhan, Michael J Keating, Timothy G Call, Jennifer R Brown, Michelle Stevens-Brogan, Yunfeng Li, Fong Clow, Danelle F James, Alvina D Chu, Michael Hallek & Stephan Stilgenbauer. (2016) Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. The Lancet Oncology 17:10, pages 1409-1418.
Crossref
Crossref
Bradley Heraly & Vicki A. Morrison. (2015) How I treat chronic lymphocytic leukemia in older patients. Journal of Geriatric Oncology 6:5, pages 333-340.
Crossref
Crossref
Michael Doubek, Yvona Brychtova, Anna Panovska, Ludmila Sebejova, Olga Stehlikova, Jana Chovancova, Jitka Malcikova, Jana Smardova, Karla Plevova, Pavlina Volfova, Martin Trbusek, Marek Mraz, Denisa Bakesova, Jakub Trizuljak, Marketa Hadrabova, Petra Obrtlikova, Josef Karban, Lukas Smolej, Alexandra Oltova, Eva Jelinkova, Sarka Pospisilova & Jiri Mayer. (2015) Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study. American Journal of Hematology 90:5, pages 417-421.
Crossref
Crossref
Polina Shindiapina, Jennifer R. Brown & Alexey V. Danilov. (2014)
A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in
TP53
. British Journal of Haematology 167:2, pages 149-161.
Crossref
Crossref
John C. Byrd & Joseph M. Flynn. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1958
1978.e7
.
Kirsty Cuthill & Stephen Devereux. (2013) How I treat patients with relapsed chronic lymphocytic leukaemia. British Journal of Haematology 163:4, pages 423-435.
Crossref
Crossref
Carlo Visco, Silvia Finotto, Fabrizio Pomponi, Roberto Sartori, Francesco Laveder, Livio Trentin, Rossella Paolini, Eros Di Bona, Marco Ruggeri & Francesco Rodeghiero. (2013) The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high‐risk patients with chronic lymphocytic leukemia. American Journal of Hematology 88:4, pages 289-293.
Crossref
Crossref
Martin Trbusek & Jitka Malcikova. 2013. Advances in Chronic Lymphocytic Leukemia. Advances in Chronic Lymphocytic Leukemia
109
131
.
Kang Lu & Xin Wang. (2012) Therapeutic advancement of chronic lymphocytic leukemia. Journal of Hematology & Oncology 5:1.
Crossref
Crossref
David Oscier, Claire Dearden, Efrem Eren, Christopher Fegan, George Follows, Peter Hillmen, Tim Illidge, Estella Matutes, Don W. Milligan, Andrew Pettitt, Anna Schuh & Jennifer Wimperis. (2012) Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. British Journal of Haematology 159:5, pages 541-564.
Crossref
Crossref
Lukáš Smolej, Michael Doubek, Anna Panovská, Martin Šimkovič, Yvona Brychtová, David Belada, Monika Motyčková & Jiří Mayer. (2012) Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. Leukemia Research 36:10, pages 1278-1282.
Crossref
Crossref